Elanco Animal Health (NYSE:ELAN) CFO Robert Vanhimbergen Purchases 6,950 Shares

Elanco Animal Health Incorporated (NYSE:ELAN) CFO Robert Vanhimbergen bought 6,950 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average price of $21.64 per share, with a total value of $150,398.00. Following the completion of the acquisition, the chief financial officer owned 124,233 shares in the company, valued at approximately $2,688,402.12. The trade was a 5.93% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Elanco Animal Health Trading Up 2.0%

NYSE:ELAN opened at $21.72 on Tuesday. The company’s 50 day moving average is $21.75 and its 200-day moving average is $18.16. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $23.70. The firm has a market cap of $10.79 billion, a price-to-earnings ratio of 361.98, a P/E/G ratio of 2.89 and a beta of 1.86.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. Elanco Animal Health’s revenue was up 10.4% compared to the same quarter last year. During the same period last year, the business posted $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Institutional Trading of Elanco Animal Health

Several institutional investors have recently made changes to their positions in ELAN. SJS Investment Consulting Inc. lifted its stake in Elanco Animal Health by 2,563.5% during the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after purchasing an additional 1,333 shares during the period. Huntington National Bank raised its holdings in shares of Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after buying an additional 1,087 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its position in shares of Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after buying an additional 900 shares during the period. Farther Finance Advisors LLC boosted its stake in Elanco Animal Health by 79.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock valued at $43,000 after buying an additional 951 shares in the last quarter. Finally, First Horizon Advisors Inc. grew its position in Elanco Animal Health by 184.3% in the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after acquiring an additional 2,414 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ELAN has been the subject of several recent analyst reports. Stifel Nicolaus increased their target price on Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Barclays initiated coverage on Elanco Animal Health in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 price objective for the company. Argus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research report on Wednesday, November 19th. Finally, Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $22.78.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.